Liver metastasis is a major limiting factor to the prognosis of colorectal cancer.
Background and purpose of this study
Liver metastasis is a major limiting factor to the prognosis of colorectal cancer.
Recently the progressive surgical removal of metastatic liver tumors becomes practical because of development of intraoperative ultrasound technique and improves survival rate when they are resectable.
Even in unresectable cases there are reports of efficacy of intra hepatic arterial infusion of chemotherapeutics (HAI), trans-arterial embolization (TAE) and microwave coagulation necrosis (MCN).
To contribute to better result after surgical removal of metastatic liver metastases it is inevitable to control metastasis in the residual liver and extra-hepatic metastasis especially to lungs.
We have tried to use intra-hepatic arterial infusion of 5-FU to control metastasis in the residual liver but the hepatic arterially infused 5-FU is not expected to work on extra-hepatic metastases because it is deactivated in liver. The systemic chemotherapy should be added to this situation but the application of cytotoxic chemotherapeutics in early postoperative stage is not practical at all from the point of their adverse effects.
Antineoplastons are naturally occurring peptides and amino-acid derivatives which control neoplastic growth and have been found in blood and urine under the concept of biochemical defense against cancer. They work on divert mechanism of action.
Researchers reported its antagonism against chemical and viral carcinogen, competitive up take of tumor cells against l-glutamine which is nitrogen source to tumor cells which lead G1 arrest in tumor cells, induction of cell differentiation in tumor cells, deactivation of oncogenes, activation of tumor suppressor genes through the alteration in DNA methylation status. And most of all they are quite non-toxic.
Antineoplastons could be combined with other chemotherapy because of less toxicity and also restored effect of chemo-resistance in tumor cells could be expected by Antineoplastons.
Phase I toxicological clinical study conducted in Kurume University Hospital from 1988 showed only minor adverse effects such as skin rash, excess gas, rigid finger, headache, lowered cholesterol.
We experienced a case of long term survive from multiple liver metastases from colon cancer. This case motivated us to conduct this study to evaluate efficacy of Antineoplaston A10 and AS2-1 as adjuvant therapy after hepatectomy for liver metastases from colorectal cancer. In Antineoplaston group, Antineoplaston A10-Injection and AS2-1 were administered from day 15 after liver surgery in addition to HAI same as in control group with a starting dose of 30 g/day of intravenous A10-Injection using a pump system to maximum dose of 100 g/day for more than 3 days. After completion of the i.v. administration of A10-Injection for a week, 10 g/day of AS2-1 was administered orally for 1 year.
5) Primary Study Endpoints: The efficacy and safety endpoints will be
Cause-specific survival rate, Disease free survival rate, Degree of recurrence, frequency, severity of adverse events. 6) Total number of patients: a total of 50 patients will be enrolled with 25 patients randomized to one of two treatment groups.
7) Duration of Study: The study will conduct from April 1998 to December 2004 and the prognosis of patients will be followed for at least 5 years.
Purpose of the study
To test efficacy and safety of Antineoplaston A10 and AS2-1 in adjuvant use in addition to HAI (5-FU) after hepatecomy for metastatic liver cancer from colon.
Eligibility 1) Inclusion Criteria
Patient who underwent curative hepatectomy or thermal ablation for liver metastases histologically confirmed as a metastasis from colon.
2) Exclusion Criteria 
Informed Consent
It is the responsibility of the investigator to provide oral and written information about this study and obtain to obtain a sighed informed consent from each patient participating with free will in this study prior to enrollment.
In case of the patient who is unable to understand what this study about, informed consent should be obtain from a person representing patient benefit legally. In case of the patient whose age is under 20 years informed consent should be obtained from the patient and legal representative.
The following issues should be fully explained before getting informed consent.
1) The purpose and method of this study.
2) Expected efficacy and toxicity.
3) Other therapeutic modalities could be applied to the disease. 
Antineoplaston A10 Injection and AS2-1
On 15 th day after liver surgery Antineoplaston A10 Injection (30 g/day) starts to be infused through the catheter instituted in great vein and increase the dose up to maximum 100 g/day and keep this dose for 3 days. Then Antineoplaston AS2-1 10 g/day (at breakfast, lunch, dinner and before sleep) starts to be administered and continued for one year.
8．Randomization Eligible patients are randomly assigned to receive systemic antineoplastons plus 5-FU HAI (AN arm) or 5-FU alone (control arm) by minimization method using number of metastases (1-3 vs >4) and presence or absence of prior extra-hepatic metastases which were removed completely at the time of surgery.
Drugs during the study period
No other anti-cancer drugs should be used during the study period.
No limitation of use of anti-histamine or digestive medication is applied.
10. Therapy during the study period 
8) Preserve frozen serum
The patient's serum is preserved frozen for measurement of newly developed tumor marker or additional tests necessary in future.
9) Adverse events
Adverse events other than subjective and objective symptoms happening during the study period should be graded in severity according to CTCAE version 2 and recorded with date, time of event and treatment and response.
10) Diary
Patient is requested to record any abnormal symptom, frequency of symptom, duration of symptom he (she) feels in diary.
Withdrawal criteria
The study should interrupt in cases with following reasons 
Evaluation of efficacy
Efficacy of the testing drug should be evaluated by comparing cause specific survival, time to intra-hepatic recurrence, degree of extension of recurrence and time to extra-hepatic recurrence between Antineoplatstons treated group and control group.
15. Serious adverse effects during the study should be reported immediately to the safety committee and treated properly. The safety committee of this study consists of principal investigator and study investigators. The safety committee should be open to patient's contact 24 hours a day.
Follow up
Treatment of patient disease after the study completed will be depending on attendant physician's decision, the prognosis of patient will be followed up to 5 years after study treatment.
Sample size
Statistical consideration for obtaining significance at 5 years survival needs 25 patients in each group making total 50 patients.
Time to start the study
The study starts from April, 1998 for 10 years.
End of the study
The study will ends enrollment as soon as 50 patients finish the study treatment. 
